



## **AZATHIOPRINE AND BIOLOGICAL TREATMENT GENETIC ASSOCIATION WITH CLINICAL RESPONSE AND TOXICITY IN INFLAMMATORY BOWEL DISEASE PATIENTS**

Nashwa Eltantawy<sup>1</sup>, Amira B. Kassem<sup>2</sup>, Islam Abd El-Hamid Elzayyadi<sup>3</sup>, Ahmed A. Elberry<sup>4</sup>, Layla M. Salah<sup>5</sup> and Mohamed EA Abdelrahim<sup>6\*</sup>

<sup>1</sup>*Department of Clinical Pharmacy, Faculty of Pharmacy, Horus University, New Damietta Egypt*

<sup>2</sup>*Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Damanhur University, Egypt*

<sup>3</sup>*Department of Hepatology & Gastroenterology, Faculty of Medicine, Mansoura University, Egypt*

<sup>4</sup>*Department of pharmacology, Faculty of Medicine, Beni-Suef University, Egypt*

<sup>5</sup>*Department of Clinical pathology, Faculty of Medicine, Mansoura University, Egypt*

<sup>6</sup>*Department of Clinical Pharmacy, Faculty of Pharmacy, Beni-Suef University, Egypt*

Inflammatory Bowel Disease (IBD) involves a variety of conditions, particularly Crohn's disease (CD) and ulcerative colitis (UC). IBD is characterized by a chronic inflammatory process of the patient's gut. This review aims to summarize the pharmacogenetics of biologics approved for IBD and the correlation with azathioprine-metabolizing enzymes and adverse reactions, therefore highlighting a likely relationship between particular polymorphisms and therapeutic response. Therefore, we reviewed and discussed the activities of therapeutic drug monitoring (TDM) protocols that use monoclonal antibodies (mABs) with a particular attention to the integration of other actions aimed to exploit the most effective and safest medications for IBD cases. The pharmacotherapy of IBD (CD and UC) has experienced a great advancement with the advent of mABs which have peculiar pharmacokinetic properties differentiating them from chemical agents, like aminosalicylates, antimetabolites (e.g., azathioprine (AZA), 6-mercaptopurine (6MP)), and methotrexate, and immunosuppressant agents (steroids and cyclosporine). But clinical studies showed that biologics might have pharmacokinetic variability which can affect the anticipated clinical outcomes, beyond primary resistance phenomena. Thus, TDM protocols are applied to the doses of medications according to the required serum mABs levels. This aims to maximize the favourable effects of mABs and minimize the toxicity. But, the presence of particular genetic polymorphisms in patients might determine a different outcome in response to treatment, indicating the heterogeneity of the effectiveness among IBD cases. Indeed, many reports demonstrated significant associations between polymorphisms and response to biologics. In conclusion, the improvement of TNF-, TNFR and IL-1 pharmacogenetics could be the best approach toward a targeted treatment for IBD. Pre-therapy genotyping has to be integrated with IBD therapeutic guidelines, as it is the most suitable approach to choose the most appropriate biologics for each case. Also, the addition of pharmacodynamic markers (including serum, cellular, or tissue concentrations of TNF-alpha and IL-8) might boost the predictive performance of models and, eventually, control the disease with a significant improvement in quality of life (QOL).

**Key words:** Pharmacogenetic, genetic polymorphism, inflammatory bowel diseases, Crohn's disease, ulcerative colitis, SNPs, Genotype, azathioprine, Thiopurine, Biological therap

### **INTRODUCTION**

Inflammatory Bowel Disease (IBD) mainly Crohn's disease (CD) and ulcerative colitis (UC) IBD, is a significant aetiology of

chronic gastrointestinal (GI) disease all over the world, with various manifestations and multifactorial nature. Together with marching industrialization, IBD has globalized gradually many epidemiologic studies revealed a stable

or reducing incidence in developed countries<sup>1-3</sup>. CD and UC are characterized by remissions and relapses with complex interactions between genes, environmental stimuli, and immune response<sup>4</sup>.

CD and UC the 2 types of IBDs depend on many therapy classes including aminosalicylates, antimetabolites (i.e., AZA, 6MP), and immunosuppressants (corticosteroids and cyclosporine). Such medications can control IBD manifestations with many systemic toxicities, unfortunately, these treatments failed to control the disease in variable percentages of patients<sup>5</sup>.

The commonest types of IBD worldwide is UC, characterized by diffusely friable colon mucosa with superficial erosions and hemorrhage<sup>6</sup>. The early disease appears in the patient's rectum, and then undergoes proximal proliferation in a continuous manner<sup>7</sup>.

IBD is highly prevalent in Northern European and North American countries may be due to a westernized environment and lifestyles, nine to twenty cases are reported among every 100,000 persons per year<sup>8</sup>. UC is more frequent in the adult population while is more prevalent in the children<sup>9</sup>.

On the other side, Appendectomy protects against the UC for unknown causes<sup>10</sup>, while in some cases, appendectomy following a UC diagnosis was found to actually worsen its course<sup>11</sup>. Appendectomy before 20 years of age was linked to a decreased UC incidence; while the opposite is true for CD. Also, appendectomy has been found to decrease the risk of UC by 69%<sup>12&13</sup>.

A vegetarian diet was found to protect against the UC development<sup>14</sup>, signifying that a shift from plant-based diet to processed food could enhance UC risk in developing countries<sup>15</sup>.

UC is a bi-modal pattern disease as its main peak appears between 15 and 30 years of age, while the second, and less severe one happens between 50 and 70 years of age. Many reports indicated that the disease is more common in men, while other reports noted no preference in terms of gender. Also the use of NSAIDs is correlated with the onset or relapse of UC<sup>16</sup>.

Smoking is a crucial risk factor for CD while stopping of smoking has been as described a risk factor for UC. How smoking

either causes or provides protection from UC is unclear<sup>17</sup>.

Other globally indicated risk factors for UC include factors which influence gut microbiota and, thus, its immunity. They include antibiotics<sup>18</sup>, dietary alterations, including the extensive utilization of food additives<sup>19, 20</sup>, as well as psychiatric comorbidity<sup>21</sup>.

It is difficult to understand the complex gut-brain axis, some studies explained the influence of psychiatric comorbidity in UC course to be mediated through the gut microbiota<sup>22</sup>.

### Genetic factors

Many patients have a positive family history of IBD. This was revealed in about 10% and to 25% of patients in Western countries however was significantly lower (less than 5%) in Asian countries<sup>23</sup>. A study reported that concordance rates in monozygotic twins with IBD were 35% and 16% for CD and UC, respectively, signifying genetic background<sup>24</sup>. Genome-wide association studies recognized 163 loci<sup>25</sup>. Another study found that ATG16L1 and TNFSF15 were linked to CD<sup>26</sup>. In general, such genetic variants explain approximately 13.6% of CD and 7.5% of UC patients<sup>25</sup>.

Patients with IBD usually necessitate therapy all over their life and the availability of pharmacological therapy is limited to certain medications such as: aminosalicylate, corticosteroids, immunosuppressant agents, biologicals and antibiotic agents while thiopurines drugs is an established second-line medications to maintain remission<sup>7&27</sup>.

Thiopurines, 6M are considered the 1<sup>st</sup> choice immunomodulating agents for treating IBD. They are used for managing inflammatory UC, CD and chronic inflammatory GI diseases<sup>27</sup>.

Thiopurines are well tolerated by most IBD patients, approximately one-third of patients have their medications modified or stopped because of several side effects<sup>28&29</sup>. Newer pharmacologic treatments, such as mABs with their targeted activity against inflammation and their tolerability, mABs represent a new era for intense research<sup>29</sup>.

## **Different therapeutics strategies of IBD**

### **Thiopurines in IBD Treatment**

Thiopurines have a significant role in CD to maintain remission in steroid-dependent individuals which was confirmed by a meta-analysis of six reports analyzed four hundred and eighty-nine patients<sup>30</sup>. But thiopurines drugs are not recommended for use in all cases with newly diagnosed CD for maintaining remission. Early introduction of thiopurines might assist in disease control<sup>31</sup>, although the continuation is advised for those receiving thiopurines drugs for long-term maintenance of remission as it was revealed that there was a higher risk of CD recurrence after drug discontinuation<sup>32</sup>.

Thiopurine treatment must not be utilized alone to control CD. According to many studies, a combination of thiopurine with infliximab (IFX) is suggested for complete remissions in moderate to severe cases that haven't responded to conventional treatment and have not utilized AZA in the early stage<sup>33</sup>.

Clinical practice proved that thiopurines failed to achieve maintained remission in many cases, which is recognized as an inadequate response to thiopurine treatment<sup>34</sup>. No reports do exist that a thiopurines/IFX combination could be beneficial for accomplishing remission, however this combination might help reduce IFX immunity<sup>35</sup>.

Both UC patients and CD patients delivered resistance to thiopurines. However, in these patients, it is suggested to shift to biological treatment or use thiopurines/IFX combination<sup>36</sup>.

Research by the Study of Biologic and Immunomodulator Naive Patients in Crohn's Disease (SONIC) compared IFX therapy alone and thiopurines/IFX combination in cases with no response to steroids. This study confirmed that combination treatment showed greater rates of remission at week 26 in comparison to IFX alone<sup>35</sup>.

Thiopurines were indicated for mild to moderate UC cases that had recurrent relapses with corticosteroids. In a retrospective study, the remission rate in those receiving AZA was 58% but improved to 87% following 6 months of dosage<sup>37</sup>. Consequently, those having significant relapse who respond to corticosteroids, cyclosporine, and IFX with

thiopurines are to be utilized to maintain remission<sup>37</sup>.

The course duration of AZA did not influence relapse rate after treatment was stopped which was approved in a study of 622 cases having CD and UC, remission rates following 6 months of AZA were 64% in CD and 87% in UC. Following AZA stoppage, the percentage of cases that remained in remission was 0.63 after 12 months, 0.44 after 3 years, and 0.35 after 5 years<sup>37</sup>.

Long term safety should be taken into consideration when choosing to start AZA in IBD, most observational studies suggested preservative and continuous monitoring due to the risk of non-melanoma tumors and lymphomas during long-term thiopurine therapy<sup>38</sup>. Side effects were recorded in 9.0% (22/245) of cases of thiopurine therapy versus 2.9% (9/311) placebo treatment<sup>39</sup>. We should notice that abnormal therapeutic concentrations of 6TGN can lead to hepatic toxicity, myelosuppression, pancreatitis, or GI intolerance<sup>28</sup>. (Fig. 1).

Adverse reaction mainly is dose-dependent as myelosuppression, leukopenia, which appears in about 20% of IBD cases because of *TPMT* gene polymorphisms<sup>40</sup>, although Thiopurine treatment can also cause myelosuppression, irrespective of *TPMT* activity which can occur even several months following the start of treatment in individuals with no *TPMT* gene polymorphisms<sup>41</sup>.

The main cause of treatment discontinuation is Myelosuppression<sup>42</sup>. Moreover hepatic toxicity can be also induced by thiopurines, characterized by high transaminases, hepatitis, or hepatic veno-occlusive disease. About 5% of those receiving AZA or 6MP suffer from pancreatitis of unknown origin, mostly in the first 30 days of therapy<sup>43</sup>.

Furthermore, GI disturbances including nausea, emesis pain and other Side effects which lead to discontinuation<sup>44</sup>.

### **Monoclonal antibodies used in inflammatory bowel diseases**

There is no doubt that the initiation of biologicals with monoclonal antibodies provides significant benefits in UC and CD treatment. They improve the manifestations, inflammation and quality of live (QOL).

Furthermore, the magnitude of their benefits has increased with improves understanding of how best to utilize them<sup>5</sup>.

TNF $\alpha$  is the main target of the mABs which used in IBD. It promotes cellular proliferation and differentiation as well as the proinflammatory response. We should reserve IFX, adalimumab and golimumab for moderate to severe IBD poorly responding to other treatments. Actually, they can improve disease control, reducing hospitalization and surgery. Unfortunately, patients on such valuable therapies might experience disease relapse<sup>45</sup>.

Until now, the cause of failure is unknown, but possible risk factors represented by individual are alterations in pharmacokinetic and pharmacodynamics properties or immunogenicity so, dose optimization for every patient in TDM protocols suggested to be valuable. Newly mABs target extra-cellular proteins which have a role in IBD onset and maintenance<sup>46</sup>.

**Infliximab (IFX)**

The structure of a recombinant monoclonal antibody of IgG1 kappa subclass is 25% murine and 75% human sequences. Infliximab has a variable murine Fab'region connected to human IgG1 constant region by bisulfide bonds<sup>47</sup>. Table (1)

There is evidence from clinical trials involving cases with RA, psoriatic arthritis, or ankylosing spondylitis that blocking the drug's efficacy due to the existence of antibodies

against the anti-TNF- $\alpha$  molecule. These results reveal the development of a fully human anti-TNF- $\alpha$  molecule to prevent the immunogenic effects and antibodies' production which might drug's efficacy and safety in trials with CD patients, noting that IFX has a cytotoxic and apoptotic like action<sup>48</sup>.

Furthermore, the potentiality to induce immune genicity can be done by all exogenous proteins while fully human proteins could be non-immunogenic at all. Table (1)

**Adalimumab (ADA)**

This is a fully humanized recombinant monoclonal antibody with direct TNF-  $\alpha$  inhibitory effect, cytotoxicity and apoptosis. It is structured basically of human-derived variable regions and a human IgG: j constant region<sup>48</sup>. ADA lower circulatory IL-6 and acute phase proteins, like CRP. It is shown that ADA stimulating apoptosis through reverse signaling in blood monocytes, leukemia cells, and lamina propria T-lymphocytes<sup>48</sup>, also it has the ability to promote the proliferation of antibodies in many cases<sup>49</sup>.

Several clinical trials have confirmed that the generation of antibodies against ADA is less frequently than that for IFX. clinical study revealed that 9.2% of CD cases that have lower trough serum IFX values developed ADA antibodies. Moreover, three clinical studies indicated that 5% only of ADA treated rheumatoid arthritis patients developed ADA neutralizing antibodies<sup>49</sup> Table (1).

**Table 1:** Approved monoclonal antibodies in IBD therapy; IL, interleukin; IV, intravenous; SC, subcutaneous (50).

Biologic treatments	Trade name	Route	Approved use	Mechanism
Infliximab	Remicade Remsima inflectra	IV	CD and UC	TNF antagonist
Adalimumab	Humira	IV	CD and UC	TNF antagonist
Golimumab	Simponi	SC	UC	TNF antagonist
Ustekinumab	Stelara	IV induction SC maintenance	CD	Anti-IL-12 & 23
Vedolizumab	Entyvio	IV	CD&UC	Anti-integrin

**Vedolizumab (VDZ)**

VDZ prevent the migration of alpha-4 beta-7 integrin molecules that expressed on gut-specific lymphocytes into the GI

parenchyma and the consequent inflammatory response. Although all biologics have a systemic immunosuppressive effect, VDZ is

unique in its gut-selective mechanism of action<sup>50</sup>.

The largest cohort to date which has been performed by US VICTORY consortium (Vedolizumab health outcomes in IBD) established that among 212 CD cases, the rate of clinical remissions at one year was 35%<sup>51</sup>. Moreover, such rate must be taken in the consideration of the high previous anti-TNF inhibitor exposure rate (90%)<sup>52</sup> Table (1).

The reduced response rates in observational studies is due to relatively increased rates of prior anti-TNF utilization confirmed that the rates in the phase III GEMINI trials of VDZ (48% in GEMINI I and 62% in GEMINI II) are a marker of the complexity of patients observed in practice. Also, high prior anti-TNF exposure was revealed in several other 'real-world' cohort studies<sup>53</sup> Table (1).

### **Ustekinumab (UST)**

UST is a recently NICE-approved monoclonal antibody for CD treatment. It binds to IL-12 and IL-23 and prevents activation of antigen presenting cells and their differentiation into Th1 and Th17 lymphocytes<sup>54</sup>. Consequently, the inflammatory cascade which involves the formation and secretion of many cytokines (e.g. IFN- $\gamma$ , IL2, IL10, IL22 and TNF- $\alpha$ ) is decreased<sup>50</sup>.

Anti-TNF-refractory cases that initiated therapy as long ago as 2011 found to respond with 39% and 60% at 3 and 6 months, respectively in the real-world CD Canadian cohort (n=167) with remission rates of 15% and 25%<sup>54</sup>. Such figures might be utilized in patient's counseling in terms of possibility of benefit and certainly are optimistic, even in the face of anti-TNF non-response<sup>55</sup> Table (1).

### **Golimumab**

Fully human monoclonal IgG1 antibody developed by Janssen Biotech, Inc. Golimumab is utilized for moderate to severe UC in adults not responding to conventional treatment such as steroids and 6-MP or AZA, or have intolerance to or contraindications for these drugs. Increased serum and tissue concentrations of TNF- $\alpha$  have been implicated in the pathophysiologic process of many chronic inflammatory disorders such as CD and UC<sup>56</sup>. It was demonstrated that cytokines,

chemokines, and growth factors have significant roles in the pathophysiologic process of IBD. Golimumab, like other anti-TNF agents, acts by direct binding to the soluble and transmembrane precursor forms. But preclinical studies demonstrated that golimumab has a greater binding affinity compared with IFX or adalimumab for the soluble and transmembrane TNF- $\alpha$ . To prevent TNF- $\alpha$  binding to its receptors, golimumab suppresses the biological activity of TNF- $\alpha$ <sup>57</sup>. There are 2 TNF- $\alpha$  receptors (TNFR1 and TNFR2), and their activation by TNF- $\alpha$  triggers an intracellular signaling cascade, leading to release of cytokines, cellular proliferation, and apoptosis. TNFR1 activation induces nuclear factor- $\kappa$ B (NF $\kappa$ B), which undergoes translocation to nucleus to activate the transcription of many pro-inflammatory cytokines including IL-8, IL-1, IL-6, COX-2, and TNF- $\alpha$ <sup>58</sup> Table (1).

### **Positioning of monoclonal antibodies**

The choice of first-line biological treatment according to the mechanism of action is very critical. Head-to-head randomized control trials data show the benefit of a certain approach over other approaches. However, these data cannot predict the response of individual patients to each medication<sup>59</sup>.

Many factors are incorporated in the choice of biological drugs, like the high prevalence of extraintestinal manifestations or perianal disease (where anti-TNF is favored), additionally if there are comorbidities like predisposition to or history of cancer or infections (where VDZ is favored). Furthermore, the choice of suitable biological treatment must take in the consideration if it is being administered as monotherapy or in combination with an immunomodulatory<sup>60</sup>. Additional factors including patient's preference and administration route must be also taken in consideration.

In General, most active CD cases start with TNF antagonists as their first monoclonal, this class has been found to have high effectiveness in recent clinical practice. They are highly beneficial in extraintestinal manifestations and perianal disease with applying TDM to optimize their effect.

From the other side, patient who responds well to one TNF antagonist, however has a

pharmacokinetic loss of response will benefit from another anti-TNF drug<sup>60</sup> and in cases of failure of the first-line therapy, a switch out of class is then recommended.

Positioning of first-line therapy in UC is less clear except with VDZ which demonstrate adequate tolerance, strong mucosal healing data<sup>61</sup>, the longevity of effect<sup>62</sup> and minor immunogenicity<sup>63</sup>. It has to be noted that this is a significantly moving field and that the next wave of biologicals and small molecules (eg, tofacitinib and ozanimod) will add further complexity.

In cases of failure of therapy or the patients does not respond to TNF- $\alpha$  antagonists, we should shift to another anti-TNF- $\alpha$  agent. Many studies declared that antibodies formed against a particular anti-TNF- $\alpha$  agent are specific and do not influence the bioavailability of another TNF- $\alpha$  antagonist, although the studies in patients with rheumatoid arthritis, the risk of developing antibodies against certain TNF- $\alpha$  antagonist is greater among those who developed antibodies against a preceding TNF- $\alpha$  antagonist<sup>63</sup>.

#### **Combined therapy versus monotherapy**

Combination of TNF antagonist and immunosuppressants has been found to decrease the risk of antibodies production among CD cases; the magnitude of decrease is augmented when anti-TNF agents are given after a scheduled strategy<sup>29&64-66</sup>, this indicated that the rate of antibodies' production in refractory CD cases receiving IFX episodically was significantly lower than patients administering concomitant immunosuppressive agents in comparison to patients not on such agents respectively<sup>64</sup>.

**Vermeire and co-workers** have confirmed such results in their study measuring the efficacy of immunosuppressive agents in preventing antibodies' formation in IFX-treated CD patients in an on-demand schedule. AZA or methotrexate also caused a reduced incidence of antibodies in comparison to those not on immunosuppressants<sup>65</sup>.

**Hanauer et al.** confirmed that the risk of immunogenicity can be reduced by concomitant usage of immunosuppressives in cases administering IFX in a scheduled

approach comparing with patients receiving IFX monotherapy<sup>66</sup>.

The SONIC trial investigated rates of antibodies formation in CD cases that were naive to immunosuppressive and TNF antagonist which randomized to receive AZA or IFX or their combination, revealed that the antibodies production was considerably lower in patients taking the combination treatment than in those on IFX alone<sup>35</sup>.

**Feagan and colleagues** also found that the combination of methotrexate and IFX in CD cases significantly decreased the rate of antibodies production (4% in cases administering combination therapy versus 20.4% in those administering infliximab alone—following a scheduled regimen)<sup>67</sup>.

Similarly, to infliximab, ADA could also stimulate the production of antibodies this risk is also diminished when mAbs are administered together with immunosuppressants following a scheduled maintenance strategy<sup>68&69</sup>. Furthermore, UC patients on combination therapy of AZA immunosuppressant with IFX showed reduced antibodies production and increases IFX trough levels<sup>67&70&71</sup>.

Regarding efficacy, it is clear that the combined therapy of IFX and AZA has more effectiveness compared with either drug monotherapy for inducing clinical remission and mucosal healing in CD and UC<sup>35, 67</sup>, this high effectiveness is because of lower rates of antibodies production and greater IFX drug concentrations in cases administered combination regimen<sup>67</sup>.

#### **Combination Therapy of Thiopurines and IFX for IBD patients**

Clinical practice and studies demonstrated that combined IFX and thiopurine therapy has more efficacy in the induction of remissions in CD and UC as compared with monotherapy of each agent.<sup>72</sup> These results could be clarified by the concept of diminished risk of immunogenicity accompanied with lower anti-IFX antibodies. Moreover, such effect is a result of a higher drug availability and consequently an enhanced clinical response<sup>72</sup>.

Thiopurines must be initiated as soon as rapid as Anti-IFX generation was observed to start at 18 days post-initiation of therapy which leads to the limitation of their use<sup>73</sup>.

Combination therapy is accompanied with many side effects, graded from infections to malignancy. Data about the safety of combination therapy come predominantly from drug registration trials, dedicated trials on combination therapy, as well as registries. Cases on combination therapy had a higher incidence of infection<sup>74</sup>.

From the other side, CD cases on immunosuppressant showed a greater risk of cancers while those administering IFX combined with immunosuppressive agents had a greater incidence of infection<sup>74</sup>.

Doses of immunosuppressive agents must be reduced as compared with in monotherapy in cases that started therapy with IFX for about a year but cases that discontinued biologic therapy, it appears better to continue AZA<sup>30</sup>.

### **Personalized medicine in IBD**

The TDM protocols along with pharmacogenetic analyses are with added benefits in following therapeutic effects of mABs and protecting individuals from toxic effects, such endpoints might be combined with indicators of clinical effectiveness and tolerability (for example: age, severity, and extension) or inflammatory biomarkers (FCP and CRP) to enhance the predictive value of the phenotypic and/or gene signature<sup>75</sup>.

Weak treatment efficacy may be associated with antibodies in patients' plasma, whereas their formation might be variable between TNF $\alpha$  antagonists, ranging from  $\leq 2.3\%$  for ustekinumab<sup>76&77</sup>, up to 25.3% for infliximab<sup>78</sup>, adalimumab (14.1%), certolizumab (6.9%), and golimumab (3.8%).

Moreover, modulation of serum antibodies formation can be achieved by simultaneous intake of other medications, including AZA and methotrexate. Actually, the IFX-AZA combination was linked to a decreased incidence of antibodies (0.9% versus 14.6%) and high Cmin values of mAB than the sole infliximab<sup>79</sup>.

The combinations of IFX-thiopurines or ADA-methotrexate are superior to bringing antibodies to non-detectable concentrations in 77% of cases that had high immunogenicity and poor response<sup>80</sup>.

Methotrexate in pediatric population significantly decreased IFX clearance and likely reduce the antibodies production, this

may be due to the fact of the formation of antibodies depends on the schedule mAB approach<sup>81</sup>. The development of ADAs is greater following an occasional intake of mABs rather than a regular approach<sup>35&81</sup>. Furthermore, the genotype at HLA-DQA1\*05 locus can predict the immunogenicity against IFX<sup>82</sup>.

### **Pharmacogenes in Inflammatory Bowel Diseases**

Enzyme activity assessment is considered a useful predicting method at the phenotype and genotype levels for pre-drug practice responses. In 1980, the first report to measure TPMT activity in human was conducted on 298 Caucasians. Investigators reported that 11.1% had intermediate activity, 89.6% had high activity, and 0.3% had no activity. The findings were linked to an autosomal codominant inheritance of a pair of alleles for low and high TPMT activities and were a big deal in pharmacogenetic science<sup>83</sup>.

Pre-therapy detection of TPMT activity might be valuable to predict thiopurines toxicities. But, evidence of their values remains unknown. For instance, cases with TPMT activity less than 30.5 EU/mL are more expected to respond to thiopurines drugs compared with cases with greater activity<sup>83</sup>. Other reports failed to report such association<sup>84</sup>. A high percentage of adults with myelosuppression effects showed a normal TPMT genotype, indicating the inaccuracy between the genotype and phenotype of TPMT<sup>85</sup>.

Genetic variability causes a reduced TPMT enzymatic activity and therefore affects the increased formation of the metabolite 6TGN. Accordingly, the Bone marrow becomes disrupted with a reduction in the production of leukocytes<sup>86</sup>. Many studies enrolling IBD patients and patients with other autoimmune disorders demonstrated the significance of applying a deeper analysis of genotyped cases<sup>87&88</sup>.

Valuable data exists in clinical research about the pharmacogenetics of thiopurines and personalized medicine aims at predicting the impact of treatment in advance by examining genetic signatures and thus adjust the drug and doses. For thiopurines, the complex biotransformation pathway of azathioprine and

6-mercaptopurine is implicated and the association between TPMT gene alleles and the metabolism rate was significant and was approved by the FDA as the first main pharmacogenetic biomarker<sup>30</sup>.

Targeted loci in IBD can be recognized and the value of various genomic markers like functional polymorphisms in the relevant genes which encode for the response to TNF treatment among IBD cases has been assessed<sup>89&90</sup>. As anti-TNF mAbs targets TNF, functional polymorphisms for TNF and TNF-receptor superfamily are a valuable region for research<sup>89-91</sup>.


Research at the level of cytokine pathways polymorphisms in (IL-1B, IL-6, IFN-gamma, TNFRSF1A, NLRP3, IL1RN, IL-18, and JAK2) and NFkB pathway (TLR2, TLR4 and NFKBIA) found a close association with response to TNF antagonists among IBD cases<sup>90&92</sup>.

The development of genomic-relevant antibodies in IBD cases has been recently identified. **Degenhardt and co-workers** demonstrated that the anti-GP2 IgA and IgG

antibodies were linked to CD and had a great discriminatory capacity for CD vs. UC<sup>93</sup>.

The new era of a genomic association with antibody expression is developed, it can recognize various loci linked to concentrations of anti-GP2 isoform beta IgG and IgA, several of which are responsible loci for IBD susceptibility, although their importance in assessing the effectiveness of TNF antagonists in CD vs. UC has not been evaluated<sup>93</sup>.


Genotyping sensitivity considerably ranges among cases having intermediate and poor enzymatic activity. From the other side, polymorphisms have been found to have a central role in thiopurines' toxicity<sup>94</sup>. In addition, numerous enzymes that involved in thiopurine biotransformation and their variable activities offers a clue for the measurement of serum metabolites which reflect the drug metabolism and distribution and facilitate the determination of the optimum dose of medications for each patient to prevent side effects and toxicities<sup>95</sup>. Figure (1).



**Fig. 1:** Side effects of thiopurines in IBD cases<sup>28</sup>.

In the case of the reduced activity of TPMT and NUDT15, the Clinical Pharmacogenetics Implementation Consortium recommends decreasing azathioprine, 6-mercaptopurine, or 6TG doses, or introducing a non-thiopurine immunosuppressive agent to

improve the efficacy of thiopurine treatment and resolve their cytotoxicity, taking in the consideration the balance between effectiveness and cytotoxicity with proper monitoring<sup>96</sup>. Figure (2)



**Fig. 2:** Potential genes causing cytotoxicity in IBD patient. Explanation of Abbreviations: 28-member soluble SLC28A2 transporter family 2; The 28-member soluble SLC28A3 transporter family 3; The soluble SLC29A1 transporter family 29 members 1; SLC29A2 Solute 29 Vector family member 2; ABCC5-ATP binding tape subclass C 28 member 5; ABCC4-ATP subclass C binding strand member 4; ABCB5-ATP Subclass B Member 5 binding tape; NUDT15-nudix hydrolase 15; TPMT- Thiopurine S-methyltransferase; GSTM-glutathione S-transferase mu; HPRT hypoxanthine phosphoribosyltransferase; ITPA- inosine triphosphatase; XDH- xanthine dehydrogenase; IMPDHA-inosine-5'-monophosphate dehydrogenase; MTHFR-methylenetetrahydrofolate reductase; ATIC-5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase; dioxxygenase dependent on FTO-alpha ketoglutarate; MOCOS-molybdenum sulfate cofactor; PACSINI-protein kinase C and a casein kinase substrate in neurons 1.

The involved genes in thiopurine metabolism include TPMT, ITPA, HPRT, XDH, GSTM1, XDH, GMPS, and NUDT15<sup>97</sup>. But, the impacts of TPMT and NUDT15 on thiopurines effects and toxicity have been reported. So, it is recommended to adjust the initial dosages of azathioprine, 6-mercaptopurine, and 6TG in accordance to TPMT and NUDT15 genotypes, and to detect the polymorphism among IBD cases<sup>96</sup>.

The tolerance, efficacy and risk associated with thiopurine toxicity also described in the term of polymorphisms<sup>97</sup>. The cytotoxicity of thiopurine treatment is dependent upon the existence of TPMT \*3A

allele in Caucasians. Simultaneously, in Latin and Asian races, it is the allele c.719A > G. Clinical trials including 219 participating IBD cases showed a difference between Caucasian and Asian races<sup>98&99</sup>.

NUDT15 gene is a critical gene for AZA-associated leukopenia in Chinese cases, c.415C > T (rs116855232) polymorphism. The C/T genotype was found in 44 cases, 16 of them administered azathioprine, and 50% had significant leukopenia. Homozygotes C/C were linked to a 17.2% likelihood of depletion of leukocytes and subsequent inflammation<sup>100</sup>. NUDT15 causes a deactivation of 6TG

triphosphate by hydrolysis to monophosphate<sup>100</sup>.

Decreased activity and the accumulation of toxic metabolites in DNA may be related to polymorphism p.R139C and alleles T/T and C/T<sup>101</sup>. It was reported that TPMT gene is responsible for leukopenia and myelotoxicity among European cases<sup>102</sup>. TPMT gene polymorphisms were associated with hepatic dysfunction in 10% of cases having a deficiency in a functional allele and 21% of heterozygotes being treated for inflammatory disorders<sup>88&103</sup>.

A total of 107 European IBD cases with the following missense variants in NUDT15 gene were considered significant: p. Gly17\_Val18del, p. Val18\_Val19insGlyVal, p.Arg139Cys, c.3G > C, c.217delA<sup>104</sup>. The new c.3G > C allele resulted in a loss of the start codon, whereas c.217delA influenced the reading frameshift. Signs of anemia and leukopenia were also detected in all patients who underwent sequencing for a non-functional TPMT allele<sup>88</sup>.

NUDT15 gene polymorphism was found in 13% of persons, and in 6%, 2 variants of genes and significant liver toxicity were detected<sup>88</sup>.

**Choi et al.** 2022 examined 131 cases with IBD, sequencing of additional 34 genes were included other than NUDT15 and TPMT. Two ATIC gene polymorphisms were significant ( $p < 0.05$ ). Polymorphism rs3821353 accounted for the intracellular concentration of 6TGN, whereas polymorphism rs16853834 and rs11706052 IMPDH2 gene were associated with the ratio of 6TGN and the administered dose of thiopurines. The activity of ITPA rs6139036 was clearly related to the concentration of 6MMPN metabolite and the maintenance dose of the medication were associated with<sup>105</sup>.

The same result from last analysis was showed for polymorphism rs8362 of ITPA gene<sup>106</sup>. In IBD children and in the group having other autoimmune diseases, the decreased in ITPA activity strongly related to 6MMP accumulation<sup>107&108</sup>.

In Asians, c.400G > A polymorphism of the alpha-ketoglutarate dependent dioxygenase gene (FTO) was linked to a 65% reduction in its enzymatic activity with significant leukopenia<sup>109</sup>. This gene might be regulated by

the genetic variant rs16952570. Higher WBCs were detected in cases with C/C FTO genotypes in comparison with T/T homozygous 30 days following initiating thiopurines therapy<sup>110</sup>.

Additionally, polymorphisms in encoding several other genes including HLA-DQA1\*05 have also been confirmed to be linked to response to TNF antagonists<sup>82</sup>. The polymorphism rs2647087 of HLA gene is correlated with pancreatitis among patients administering thiopurines treatment. In the non-functional C/C homozygotes, the inflammation risk was 14.6%, A/C heterozygote 4.3%, while wild-type A/A 0.5%<sup>111</sup>.

In a study that revised 15 GWAS, it was documented that 110 IBD loci were shared between UC and CD while 30 loci were specific for CD and 23 loci were specific for CD<sup>25</sup>. Moreover, a recently published GWAS involving 1,240 biological naïve cases reported a significant relationship between HLA-DQA1\*05 locus and the enhanced rate of immunogenicity and the production of antibodies against IFX and adalimumab, although the usage of the biologicals alone or combined with other medications did not influence such correlation<sup>82</sup>.

In another report on 252 IBD cases, the variant HLA-DQA1\*05 was linked to a significant increase in the risk for antibodies against IFX (HR = 7.29) with no effect of age, sex, weight, and immunomodulatory<sup>112</sup>.

The initial clinical studies investigating the effect of MOCOS gene on the metabolic pathways of thiopurines revealed its significant role in enzymatic regulation of AOX1 and XDH. But, more investigations should be conducted to completely indicate the role of MOCOS gene on cytotoxic effects. This study also examined children with IBD indicated that GMPS gene significantly underlines tolerance to the medication utilized. The mechanism of cytotoxicity was achieved by an attachment of the phosphate residue to 6-TIMP converting it to 6TGN<sup>94</sup>.

The effect of transporters in IBD is not completely declared yet. Polymorphism rs8180093 of ABCC5 gene causes resistance to mercaptopurine and affected the occurrence of leukopenia among IBD cases where SLC29 and SLC28 genes regulate thiopurines' uptake, transport and accumulation of cytotoxic

metabolites<sup>105</sup>. In fact, such impact was demonstrated in those with ALL receiving thiopurines drugs. More studies are necessary for investigating the association of their polymorphisms with the cytotoxicity of thiopurine drugs among IBD cases<sup>106</sup>.

In addition, the polymorphism in FCGR3A gene was an indicator of therapeutic response among CD cases. Of note, **Bank and colleagues** who examined 587 CD and 458 UC cases, replicated the genetic signature in a following study<sup>113</sup>. The updated signature demonstrated 10 polymorphisms involved in NFκB-, TNFα-, and cytokines' signaling. Also, cases that had risk signatures for TNFα-driven inflammation had a higher likelihood of experiencing benefits from TNFα antagonist. An additional cohort also confirmed such results in 103 IBD cases<sup>114</sup>.

Of note, the wild-type variant of polymorphism rs396991 (V158F) in FCGR3A gene was associated with the production of antibodies and decreased IFX levels. Generally, the studies demonstrated the necessity for investigating several factors to acquire genetic signatures with adequate predictive/prognostic value<sup>5</sup>.

In 2016, a meta-analysis study conducted to investigate the relation between polymorphisms in TLR2, TLR4, TLR9, TNFRSF1A, IFNγ, IL-6, and IL-1β genes and therapy response among IBD cases<sup>113</sup>.

Genetic markers might also combine with clinical or laboratory data. One cohort revealed a significant association between polymorphism rs1143634 in IL1β gene, the greater cytokines' levels at baseline, and decreased response in 29 CD and 18 UC cases, based on the clinical remission of IFX at week 14<sup>115</sup>. Also, polymorphism rs2228273 in ZNF133 was a predictor of reduced response to IFX after the initial administration<sup>116</sup>.

Microarrays, GWAS, as well as next-generation sequencing platforms have recently been employed in pharmacogenetics which enables screening for multiple genetic markers simultaneously<sup>117</sup>. Additionally, genetic markers were used in combination with clinical and laboratory data to achieve highly-performant productivity<sup>118</sup>. For example, a recent study including 231 UC Caucasians reported 2 genetic signatures of 8 and 12 SNPs linked to primary non- response (PNS) and

duration of response (DR) to TNF-α antagonists, respectively<sup>119</sup>.

It is important to mention that genetic risk scores of PNS and DR had no associations with IFX concentrations or antibodies' development, so the correlations of such SNPs might be through another mechanism than pharmacokinetics or antibodies' development<sup>5</sup>.

Another research assessed whether the gene signature developed for IFX would also be a predictor for mucosal healing in UC cases, clinical response, and remission following golimumab administration<sup>120</sup>. The results showed that genetic signature was predominantly drug-specific as it failed in identifying cases that achieved remissions or responses following golimumab administration. This study also assessed the likely diagnostic factor for TNFα antagonists<sup>121</sup>. Furthermore, in 474 IBD European cases, rs116724455 in TNFS4/18 and rs2228416 in PLIN2, were predictors for treatment effectiveness<sup>122</sup>.

In the context of genetic polymorphism and drug efficacy, a study from Spain reported a significant relationship between 5 polymorphisms in TNF-α or NFκB pathways and serum levels of IFX (rs5030728 in TLR4 and rs11465996 in LY96) and adalimumab (rs1816702 in TLR2, rs2569190 in CD14, and rs3397 in TNFRS1B) in children with IBD<sup>123</sup>. However, dissimilar regimens and patients' number in subgroups are considered weak points for those associations<sup>124</sup>.

Finally, biomarkers might have an important role in distinguishing pediatric- from adult-onset IBD. For instance, GWAS has shown SNP differences in the polygenic architecture between pediatric and adult-onset IBD [69]. Which could be the valuable genetic markers to examine the role and significance of accumulated rare and detrimental variants in involved pediatric- and adult-onset<sup>90</sup>.

## Discussion

Taking into account the necessity for using thiopurines for IBD patients and the challenge of personalized medicine, thus conduction of more pharmacogenetic studies and metabolite monitoring appears natural and obvious<sup>30&125</sup>

The era of anti-TNF mAbs give promising treatment for better outcome of the disease, even so, responding to these therapies failed in

high percentage of patients but the optimization of the treatment will lead to improvement. patients who loss of response could be managed by monitoring plasma drug levels and ADAs (immunogenicity)<sup>126</sup>.

The kinetics of mAbs is a persistent need to indicate patient's response, characteristics of the disease and many factors related to patients affect the PK of mAbs. Assessment of variables that affect configuration of mAbs could help recognizing patients that taking greater doses due to the fastest clearance of the drug. Unlikely, studies merged such variables into a single PK model in aimed population have not been completed yet. From the other side, increasing numbers of mAbs treatment of IBD makes the monitoring of efficient dosing and factors influencing PK and PD of mAbs very critical steps so the success of these drugs will be established. Combined clinical, imaging, and PK studies must lead to worth advances in how to customize drug dosage and monitoring therapeutic response. Lately guiding individual dosage by PK algorithms is safer, effective and cheaper<sup>127</sup>.

Systematic demonstrated a trend toward a higher adherence to adalimumab than to IFX, showing that self-administration of adalimumab does not impair adherence to TNF antagonists in CD cases. Higher adherence rates to adalimumab might be partially elucidated by the fact that only CD patients were treated with this biologic, while IFX was prescribed for cases with CD and UC. But, differences in methods and study design between studies do not permit a direct comparison between both agents. Also, only 13 studies were included and most of them were retrospective, while four studies were available only as an abstract. Lastly, many studies included a mixed population (rheumatoid arthritis, psoriasis, and IBD), and no data were provided according to disease type<sup>128&129</sup>.

Great commitment to adalimumab than to infliximab trending action in a systemic review, presented that self-administration of adalimumab does not decline TNF antagonist committed in CD cases. while infliximab was prescribed for both CD and UC patients. Moreover just 13 retrospective study showed that. While 4 abstract was available only. Finally, mixed population of (rheumatoid

arthritis, psoriasis, and IBD), was in. unfortunately no data for disease type<sup>130</sup>.

Regarding expecting response, pharmacogenomics tests may give clue before starting the biologic treatments<sup>122</sup>. In fact, realizing how much risk of UD and CD incubate could be done by expectable biomarkers of response to mAbs called germinal genetic variants<sup>131</sup>. It's valuable that we notice that forecasting progress by a gene signature instead of a single genetic locus<sup>132</sup>.

Designing the drug treatment for each IBD cases means selecting an effective approach which can be changed immediately if there is a poor response or after toxicities appear. Furthermore, some causes may continue to improve treatment on an individual basis, besides, chronic regime of combined drugs, its narrow therapeutic index, and the gradual disease exacerbation<sup>133</sup>.

For thiopurines, methotrexate, aminosalicylates, and immunosuppressants, the mentioned strategy is also beneficial both in adults and children especially when the protocols of TDM needs chromatographic ways that can be exhausted and need experts as in case of thiopurines. Furthermore, predicting the impact of combined treatment regimens could be analyzed by pharmacogenomic, that are advantageous as second-line therapy<sup>134</sup>. for instance, German study defined genetic passport which covered multiple loci (TPMT, NUDT15, HLA-DQA1\*02:01-HLA-DRB1\*07:01, and HLA-DQA1\*05) related to thiopurines toxicity and anti-TNF $\alpha$  mAbs<sup>135</sup>.

The pharmacogenomic signature would work with clinical risk factors (i.e., prior treatment with TNF- $\alpha$  antagonists)<sup>136</sup>, moreover it will help in decreasing the coast, improve health-care systems and Quality of life (QOL)<sup>137</sup>. But exciting of rare variant alleles will decline the curve<sup>138</sup>, taking into consideration that genotyping and phenotyping are beneficial in monitoring failure and adverse reactions during treatment<sup>139</sup>.

Conversely, since the body comprises more microbes than cells, the microbiome is of great interest in research. Therefore, significant research about microbiota interaction on the effect of thiopurines' therapy is expected for IBD cases. Effenberger et al. supported this hypothesis, and described an in silico metabolic prediction analysis for those treated

with AZA or TNF antagonists. Authors evaluated the impact of microbiota on remission state and demonstrated that the predicted butyrate production showed significant improvement in those with remissions<sup>30</sup>.

Such results suggested an association between microbiota and the efficacy of immunosuppressants for IBD patients. Whether the composition of microbiota in human body might also have a role in the cytotoxic effects of thiopurines is still questioned<sup>30</sup>.

### **Perspectives in the future**

Many genetic markers are linked to anti-TNF therapeutic response in IBD and, commonly, interpretation of genetic information in a meaningful manner might be challenging [66]. The significance of various genomic markers has been assessed, mainly markers that might affect anti-TNF therapeutic response, finding that not only polymorphisms of TNF and TNFR have a role to therapeutic response after pharmacotherapy, but also polymorphisms of cytokines and immunological pathways. In spite of the fact that they cannot be fully considered predictive markers as they require validation, these markers are not altered with time and many of them are promising in clinical practice. Thus, relationship between SNPs and response to biologics in IBD was assessed in many pharmacogenetic studies, reporting a relationship between some SNPs and response to biologics<sup>113</sup>.

Genetic polymorphisms linked to therapy outcome in IBD cases receiving biologics, have been assessed to discover a possible pharmacogenetic approach for predictive value. So far, no recommendations do exist about the search for genetic polymorphisms incorporated in the pathogenetic process of IBD as part of therapeutic optimization<sup>89</sup>.

In particular, polymorphisms of TNF and TNFR genes, were linked to inadequate response, in addition to the rs1799724, rs767455, rs1061624 and rs976881. In contrast, other polymorphisms in such genes were linked to a good response, for example rs361525 and rs3397. The majority of polymorphisms in innate immunity genes showed no association with therapeutic response; but, TLR4 rs5030728, rs1554973, IL-1\_ rs4848306 and

IL-17 rs766748 polymorphisms were linked to a good response, whereas IL-1\_ rs1143634 was associated with a worse response. Furthermore, we reported that FasL rs763110, Caspase-9 rs4645983 and ATG16L1 rs10210302 polymorphisms were linked to with a good response; but, ATG16L1 rs2241880 polymorphism was correlated to a worse response<sup>140</sup>.

Also, the role of polymorphism which interfere with the biological therapy that targets IL-12 and IL-23 has been evaluated despite only one study linked PTPN2 rs7234029 polymorphism to poor response to Ustekinumab. Nonetheless, environmental factors including nutritional factors, lifestyle, and other medications which might interact with genetic susceptibility were not taken into consideration<sup>141</sup>.

Furthermore, the monitorization time, differences among populations, genetic heterogeneity as well as gene-gene interaction were not considered. Similarly, some statistical errors might have affected the results. Also, the included studies in the systematic review were heterogenous for many characteristics (ethnicity, biologicals administered, IBD type), a likely bias could be ascribed. Besides, only published studies were retrieved while preprint servers, another registries/results database were not included<sup>142</sup>.

The potentially overlapping data were ruled out; however some overlapping data were missed or non-overlapping data might have unintentionally ruled out. Furthermore, the degree of disease activity in patients might have been different among studies, consequently this might have introduced other biases. Also, we could not rule out that correlations were not reported due to low statistical power in many studies included in the review. Nonetheless, the systematic review has strengths: we assessed a large number of polymorphisms which could alter the effectiveness of biologics approved for IBD, offering a wide pharmacogenetic overview of current biologic therapy used to treat IBD. Furthermore, all the filtered genes which were considered, having a biologic effect, allowed a logical version of the observed effects<sup>89</sup>.

The study highlights correlations between therapy response and specific alleles based on a robust biologic or clinical effect. To conclude,

improving TNF, TNFR and IL-1 pharmacogenetics could be the most appropriate approach toward a targeted treatment for IBD, even if bias like ethnicity and different types of biologic drugs utilized must be considered. Pre-therapy genetic testing must be combined with clinical IBD therapeutic guidelines, because it is the most appropriate way to choose the most suitable biologic agent for each subject. Lastly, clinical implementation of pre-therapy genotyping can be achieved through investigating the role of target genes that can interfere with the action of other biological agents apart from anti-TNF\_ agents to recognise genetic variants of higher predictive performance<sup>143</sup>.

### Conclusion

Taking into consideration the constant necessity for using thiopurines drugs to treat IBD and the challenge of personalized medicine, extensive pharmacogenetic studies and metabolites' monitoring are needed<sup>135&144</sup>.

The safety of providing purine drugs for IBD treated has been an issue of significant argument for several years. The current knowledge supports the selection of thiopurine drugs for pregnant females with IBD. In other words, the safety concerns of these drugs are real but also uncommon.

Monitoring thiopurine metabolites and enzymatic activity allow personalized dosing in IBD cases that started therapy and what is our knowledge of pharmacogenetic biomarkers as predictors prior to therapy, such questions will be discussed in this review.

Furthermore, predictive pharmacogenetic screening has more effectiveness because of extending the TPMT gene analysis to NUDT15, and thiopurine benefit are more than its risks in most of individuals, even during pregnancy. Adjustment of thiopurine doses via measuring their metabolites is routinely recommended and is better than weight-based dose.

It is worth to know also the relations between acute cytotoxicity and concurrent incidence of TPMT and NUDT15 gene polymorphisms<sup>145</sup>. Finally, all genes involved in increasing thiopurines toxicity in IBD patients still unspecific. A lot of correlations require verification and functional studies in genome-wide research. However, expecting thiopurines

side effects in IBD cases prior to treatment induction can be done by pharmacogenetics.

- In conclusion Thiopurine effectiveness and toxicity are linked to the relative levels of metabolites. Genetic polymorphisms in metabolizing enzymes result in a large inter-individual variability in drug response and risk of toxicity.
- TPMT is one of the first pharmacogenetic tests to be incorporated in clinical practice. It is recommended before commencing thiopurines to prevent potentially myelodepression.
- TPMT enzyme activity might be valuable for determination of the starting dose.
- 6-TGN and 6-MMP monitoring is beneficial in determination of the cause of non-response to thiopurines and 6-TGN monitoring might help decrease the risk of myelodepression.
- Large prospective studies are necessary for comparing standard care with pharmacogenetics and metabolites' monitoring to confirm the role of these new investigations.
- Pharmacogenomic studies on the association between the new monoclonal antibody drugs and various genetic polymorphisms are insufficient. Moreover factors involved in immunity and inflammation are very diverse, and there is currently no clear direction for personalized medicine
- Therefore, further research is essential, and this will increase the safety and efficacy of the newly developed monoclonal antibody drugs, enabling more complete precision medicine
- This review reveals the complex genetic basis for the response to monoclonal antibody drugs among biological and it may contribute to important advances in understanding the molecular mechanisms involved in these therapies.

### REFERENCES

1. N. A. Molodecky, I.S. Soon, D.M. Rabi, W.A. Ghali, M. Ferris, G. Chernoff, E.I. Benchimol, R. Panaccione, S. Ghosh, H.W. Barkema, and G.G. Kaplan, "Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review", *Gastroenterology*, 142(1), 46-54 (2012).

2. S.C. Ng, H.Y. Shi, N. Hamidi, F.E. Underwood, W. Tang, E.I. Benchimol, R. Panaccione, S. Ghosh, J.C.Y. Wu, F.K.L. Chan, J.J.Y. Sung, and G.G. Kaplan, "Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies", *Lancet*, 390(10114), 2769-2778(2017).
3. S.C. Ng, G.G. Kaplan, W. Tang, R. Banerjee, B. Adigopula, F.E. Underwood, D. Tanyingoh, S.C. Wei, W.C. Lin, H.H. Lin, J. Li, S. Bell, O. Niewiadomski, M.A. Kamm, Z. Zeng, M. Chen, Hu P., Ong D., Ooi C.J., Ling K.L., Miao Y., Miao J., Janaka de Silva H., Niriella M., Aniwan S., Limsrivilai J., Pisespongsa P., Wu K., Yang H., Ng K.K., Yu H.H., Wang Y., Ouyang Q., Abdullah M., Simadibrata M., Gunawan J., Hilmi I., Lee Goh K., Cao Q., Sheng H., Ong-Go A., Chong V.H., Ching J.Y.L., Wu J.C.Y., Chan F.K.L., and Sung J.J.Y., "Population Density and Risk of Inflammatory Bowel Disease: A Prospective Population-Based Study in 13 Countries or Regions in Asia-Pacific", *Am J Gastroenterol*, 114(1), 107-115(2019).
4. A.N. Ananthakrishnan, "Epidemiology and risk factors for IBD", *Nat Rev Gastroenterol Hepatol*, 12(4) 205-217(2015).
5. A. Di Paolo and G. Luci, "Personalized Medicine of Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacogenetics, Therapeutic Drug Monitoring, and Beyond", *Front Pharmacol*, 11, 610806 (2020).
6. M. Harbord, R. Eliakim, D. Bettenworth, K. Karmiris, K. Katsanos, U. Kopylov, T. Kucharzik, T. Molnár, T. Raine, and S. Sebastian, "Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management", *J Crohns Colitis*, 11(7), 769-784(2017).
7. W.D. Lynch and R. Hsu, "Ulcerative Colitis, in *StatPearls*", 2022, StatPearls Publishing Copyright © 2022, StatPearls Publishing LLC.: Treasure Island (FL).
8. K. Conrad, D. Roggenbuck, and M.W. Laass, "Diagnosis and classification of ulcerative colitis", *Autoimmun Rev*, 13(4-5), 463-466 (2014).
9. J. D. Feuerstein and A.S. Cheifetz, "Ulcerative colitis: epidemiology, diagnosis, and management", *In Mayo Clinic Proceedings*, 2014, Elsevier.
10. P. Myrelid, K. Landerholm, C. Nordenvall, T. D. Pinkney, and R.E. Andersson, "Appendectomy and the risk of colectomy in ulcerative colitis: a national cohort study", *Am J Gastroenterol*, 112(8), 1311-1319 (2017).
11. A. Parian, B. Limketkai, J. Koh, S. R. Brant, A. Bitton, J.H. Cho, R.H. Duerr, D.P. McGovern, D.D. Proctor, and M.D. Regueiro, "Appendectomy does not decrease the risk of future colectomy in UC: results from a large cohort and meta-analysis", *Gut*, 66(8), 1390-1397(2017).
12. S. Danese, R. Banerjee, J.F. Cummings, I. Dotan, P.G. Kotze, R.W.L. Leong, K. Paridaens, L. Peyrin-Biroulet, G. Scott, and G. Van Assche, "Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy–Access to Rapid Treatment (iSTART) approach", *Intest Res*, 16(4), 522(2018).
13. M. Flamant and X. Roblin, "Laboratory Evaluation, Including Novel Diagnostic Markers", *In Crohn's Disease and Ulcerative Colitis*, Springer, 233-242(2017).
14. A.D. Amarpurkar, D.N. Amarpurkar, P. Rathi, P. Sawant, N. Patel, P. Kamani, K. Rawal, R. Baijal, A. Sonawane, and N. Narawane, "Risk factors for inflammatory bowel disease: A prospective multi-center study", *Indian J Gastroenterol*, 37(3), 189-195(2018).
15. A. Lerner and T. Matthias, "Changes in intestinal tight junction permeability associated with industrial food additives explain the rising incidence of autoimmune disease", *Autoimmun Rev*, 14(6), 479-489(2015).
16. W.K. Ng, S.H. Wong, and S.C. Ng, "Changing epidemiological trends of inflammatory bowel disease in Asia", *Intest Res*, 14(2), 111(2016).
17. C.N. Bernstein, A. Eliakim, S. Fedail, M. Fried, R. Gearry, K.-L. Goh, S. Hamid,

- A.G. Khan, I. Khalif, and S.C.Ng, "World gastroenterology organisation global guidelines inflammatory bowel disease: update August 2015", *J Clin Gastroenterol*, 50(10), 803-818(2016).
18. R. Ungaro, C.N.Bernstein, R.Gearry, *et al.*, "Antibiotics associated with increased risk of new-onset Crohn's disease but not ulcerative colitis: a meta-analysis", *Am J Gastroenterol*, 109(11), 1728-1738(2014).
  19. A. Lerner and T.Matthias, "Changes in intestinal tight junction permeability associated with industrial food additives explain the rising incidence of autoimmune disease", *Autoimmun Rev*, 14(6), 479-489(2015).
  20. J.D. Lewis and M.T.Abreu, "Diet as a trigger or therapy for inflammatory bowel diseases", *Gastroenterology*, 152(2), 398-414. e6(2017).
  21. R. Marrie, R.Walld, J.Bolton, *et al.*, "Rising incidence of psychiatric disorders before diagnosis of immune-mediated inflammatory disease", *Epidemiol Psychiatr Sci*, 28(3), 333-342 (2019).
  22. B.L. Bonaz and C.N.Bernstein, "*Brain-gut interactions in inflammatory bowel disease*", *Gastroenterology*, 144(1), 36-49(2013).
  23. L. Prideaux, M.A. Kamm, P.P. De Cruz, F.K.Chan, and S.C. Ng, "Inflammatory bowel disease in Asia: a systematic review", *J Gastroenterol Hepatol*, 27(8), 1266-1280(2012).
  24. M.E. Spehlmann, A.Z.Begun, J.Burghardt, P.Lepage, A. Raedler, and S.Schreiber, "Epidemiology of inflammatory bowel disease in a German twin cohort: results of a nationwide study", *Inflamm Bowel Dis*, 14(7), 968-976(2008).
  25. L. Jostins, S.Ripke, R.K.Weersma, R.H.Duerr, D.P. McGovern, *et al.*, "Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease", *Nature*, 491(7422), 119-124(2012).
  26. S.C. Wei, Y.H.Ni, H.I.Yang, Y.N.Su, M.C.Chang, *et al.*, "A hospital-based study of clinical and genetic features of Crohn's disease", *J Formos Med Assoc*, 110(9), 600-606(2011).
  27. M. Harbord, R. Eliakim, D. Bettenworth, K. Karmiris, K.Katsanos, *et al.*, "Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management", *J Crohns Colitis*, 11(7), 769-784(2017).
  28. M. Chaparro, I.Ordás, E.Cabré, V. Garcia-Sanchez, G.Bastida, *et al.*, "Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients", *Inflamm Bowel Dis*, 19(7), 1404-1410(2013).
  29. B. Jharap, M.L.Seinen, N.K. de Boer, J.R.van Ginkel, R.K.Linskens, J.C.Kneppelhout, C.J.Mulder, and A.A. van Bodegraven, "Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts", *Inflamm Bowel Dis*, 16(9), 1541-1549(2010).
  30. O. Zakerska-Banaszak, L.Łykowska-Szuber, M.Walczak, J.Żuraszek, A. Zielińska, and M. Skrzypczak-Zielińska, "Cytotoxicity of Thiopurine Drugs in Patients with Inflammatory Bowel Disease", *Toxics*, 10(4), 151(2022).
  31. J. Panés, A. López-Sanromán, F. Bermejo, V. García-Sánchez, M.Esteve, *et al.*, "Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease", *Gastroenterology*, 145(4), 766-774 (2013).
  32. R.K. Boyapati, J. Torres, C. Palmela, C.E.Parker, O.M.Silverberg, S.D.Upadhyaya, T.M.Nguyen, and J.F.Colombel, "Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease", *Cochrane Database Syst Rev*, 5(5), Cd012540 (2018).
  33. W. Reinisch, J.Panés, M.Lémann, S. Schreiber, B. Feagan, S. Schmidt, *et al.*, "A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease", *Am J Gastroenterol*, 103(9), 2284-2292(2008).
  34. K.M. Lee, Y.S.Kim, G.S.Seo, T.O.Kim, and S.K.Yang, "Use of Thiopurines in Inflammatory Bowel Disease: A Consensus Statement by the Korean

- Association for the Study of Intestinal Diseases (KASID)", *Intest Res*, 13(3), 193-207(2015).
35. J.F. Colombel, W.J. Sandborn, W. Reinisch, G.J.Mantzaris, *et al.*, "Infliximab, azathioprine, or combination therapy for Crohn's disease", *N Engl J Med*, 362(15), 1383-1395(2010).
  36. D. Christophorou, N. Funakoshi, Y.Duny, J.C.Valats, M. Bismuth, G. Pineton De Chambrun, J.P.Daures, and P. Blanc, "Systematic review with meta-analysis: infliximab and immunosuppressant therapy vs. infliximab alone for active ulcerative colitis", *Aliment Pharmacol Ther*, 41(7), 603-612(2015).
  37. A.G. Fraser, T.R.Orchard, and D.P.Jewell, "The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review", *Gut*, 50(4), 485-489(2002).
  38. J.F. Rahier, F.Magro, C.Abreu, A.Armuzzi, S.Ben-Horin, *et al.*, "Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease", *J Crohns Colitis*, 8(6), 443-468(2014).
  39. J. Torres, S.Bonovas, G.Doherty, T.Kucharzik, J.P.Gisbert, *et al.*, "ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment", *J Crohns Colitis*, 14(1), 4-22(2020).
  40. M. Schwab, E.Schäffeler, C.Marx, C. Fischer, T. Lang, *et al.*, "Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism", *Pharmacogenetics*, 12(6),429-436(2002).
  41. J.D. Lewis, O. Abramson, M. Pascua, L.Liu, L.M.Asakura, *et al.*, "Timing of myelosuppression during thiopurine therapy for inflammatory bowel disease: implications for monitoring recommendations", *Clin Gastroenterol Hepatol*, 7(11), 1195-201, quiz 1141-2(2009).
  42. D.Q. Shih, M.Nguyen, L.Zheng, P.Ibanez, L. Mei, L.Y.Kwan, K.Bradford, C.Ting, S.R.Targan, and E.A.Vasiliauskas, "Split-dose administration of thiopurine drugs: a novel and effective strategy for managing preferential 6-MMP metabolism", *Aliment Pharmacol Ther*, 36(5), 449-58(2012).
  43. N. Teich, W.Mohl, B.Bokemeyer, B.Bündgens, J.Büning, *et al.*, "Azathioprine-induced Acute Pancreatitis in Patients with Inflammatory Bowel Diseases--A Prospective Study on Incidence and Severity", *J Crohns Colitis*, 10(1), 61-68(2016).
  44. A. Ansari, M.Arenas, S.M.Greenfield, D.Morris, J.Lindsay, K.Gilshenan, *et al.*, and Sanderson J., "Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease", *Aliment Pharmacol Ther*, 28(8), 973-983(2008).
  45. M.J. Casanova, M.Chaparro, V.García-Sánchez, O.Nantes, E. Leo, *et al.*, "Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study", *Am J Gastroenterol*, 112(1), 120-131(2017).
  46. P. Hindryckx, N.Vande Castele, G.Novak, R.Khanna, G.D'Haens, *et al.*, "The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?", *J Crohns Colitis*, 12(1), 105-119(2018).
  47. F.S. Macaluso, J.R.F.Cummings, R.Atrey, J.Choi, and A.Orlando, "A Systematic Review on Infliximab Biosimilar SB2: From Pre-Clinical Data to Real-World Evidence", *Expert Opin Biol Ther*, 22(2), 203-223(2022).
  48. N. García-Beloso, I.Altabás-González, M.Samartín-Ucha, M.Gayoso-Rey, *et al.*, "Switching between reference adalimumab and biosimilars in chronic immune-mediated inflammatory diseases: A systematic literature review", *Br J Clin Pharmacol*, 88(4), 1529-1550(2022).
  49. I.B. McInnes, J.K.Anderson, M.Magrey, J.F.Merola, Y.Liu, *et al.*, "Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis", *N Engl J Med*, 384(13), 1227-1239(2021).
  50. M. Luzentales-Simpson, Y.C.F. Pang, A. Zhang, J.A.Sousa, and L.M.Sly,

- "Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases", *Front Cell Dev Biol*, 9, 612830(2021).
51. P.S. Dulai, S.Singh, X.Jiang, F.Peerani, N.Narula, *et al.*, "The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium", *Am J Gastroenterol*, **111**(8): p. 1147-55(2016).
  52. N. Narula, F.Peerani, J.Meserve, G.Kochhar, K.Chaudrey, *et al.*, "Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium", *Am J Gastroenterol*, **113**(9), 1345(2018).
  53. M.A. Samaan, P.Pavlidis, E.Johnston, B.Warner, J.Digby-Bell, *et al.*, "Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres", *Frontline Gastroenterol*, **8**(3), 196-202(2017).
  54. A.G. Tamilarasan, G.Cunningham, P.M.Irving, and M.A.Samaan, "Recent advances in monoclonal antibody therapy in IBD: practical issues", *Frontline Gastroenterol*, **10**(4), 409-416(2019).
  55. C. Ma, R.N.Fedorak, G.G.Kaplan, L.A.Dieleman, S.M.Devlin, *et al.*, "Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort", *Aliment Pharmacol Ther*, **45**(9), 1232-1243(2017).
  56. H.I. Brunner, N.Ruperto, N.Tzaribachev, G.Horneff, V.G.Chasnyk, *et al.*, "Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial", *Ann Rheum Dis*, **77**(1), 21-29(2018).
  57. W.J. Sandborn, B.G.Feagan, C.Marano, H.Zhang, R.Strauss, *et al.*, "Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis", *Gastroenterology*, **146**(1), 96-109.e1(2014).
  58. W.J. Sandborn, B.G.Feagan, C.Marano, H.Zhang, R.Strauss, *et al.*, "Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis", *Gastroenterology*, **146**(1), 85-95, quiz e14-5(2014).
  59. S. Singh, M.Fumery, W.J. Sandborn, and M.H.Murad, "Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease", *Aliment Pharmacol Ther*, **48**(4), 394-409(2018).
  60. N. Mitrev, N.Vande Castele, C.H.Seow, J.M.Andrews, S.J.Connor, *et al.*, "Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases", *Aliment Pharmacol Ther*, **46**(11-12), 1037-1053(2017).
  61. J.D. Feuerstein, G.C.Nguyen, S.S.Kupfer, Y.Falck-Ytter, and S.Singh, "American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease", *Gastroenterology*, **153**(3), 827-834(2017).
  62. E.V. Loftus, Jr., J.F.Colombel, B.G.Feagan, S.Vermeire, W.J.Sandborn, *et al.*, "Long-term Efficacy of Vedolizumab for Ulcerative Colitis", *J Crohns Colitis*, **11**(4), 400-411(2017).
  63. M.G. Ward, M.P.Sparrow, and X.Roblin, "Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions", *Therap Adv Gastroenterol*, **11**, 1756284818772786(2018).
  64. F. Baert, M.Noman, S.Vermeire, G.Van Assche, G D.H., A.Carbonez, and P. Rutgeerts, "Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease", *N Engl J Med*, **348**(7),601-8(2003).
  65. S. Vermeire, M.Noman, G.Van Assche, F.Baert, G.D'Haens, and P. Rutgeerts, "Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease", *Gut*, **56**(9), 1226-1231(2007).

66. S.B. Hanauer, C.L.Wagner, M. Bala, L. Mayer, S. Travers, R.H.Diamond, A.Olson, W.Bao, and P.Rutgeerts, "Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease", *Clin Gastroenterol Hepatol*, **2**(7), 542-553(2004).
67. I. Ordás, D.R.Mould, B.G.Feagan, and W.J.Sandborn, "Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms", *Clin Pharmacol Ther*, **91**(4), 635-46(2012).
68. S. Schreiber, M.Khaliq-Kareemi, I.C.Lawrance, O.Thomsen, S.B.Hanauer, J.McColm, R.Bloomfield, and W.J.Sandborn, "Maintenance therapy with certolizumab pegol for Crohn's disease", *N Engl J Med*, **357**(3), 239-250(2007).
69. W.J. Sandborn, S.B.Hanauer, P.Rutgeerts, R.N.Fedorak, M.Lukas, *et al.*, "Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial", *Gut*, **56**(9), 1232-1239(2007).
70. P. Rutgeerts, W.J.Sandborn, B.G.Feagan, W.Reinisch, A.Olson, *et al.*, "Infliximab for induction and maintenance therapy for ulcerative colitis", *N Engl J Med*, **353**(23), 2462-2476(2005).
71. G.R. Lichtenstein, R.H.Diamond, C.L.Wagner, A.A.Fasanmade, A.D.Olson, C.W.Marano, J.Johanns, Y.Lang, and W.J.Sandborn, "Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials", *Aliment Pharmacol Ther*, **30**(3), 210-226(2009).
72. G. Privitera, D.Pugliese, S.Onali, V.Petito, F.Scaldaferri, A.Gasbarrini, S.Danese, and A.Armuzzi, "Combination therapy in inflammatory bowel disease - from traditional immunosuppressors towards the new paradigm of dual targeted therapy", *Autoimmun Rev*, **20**(6), 102832(2021).
73. J.F. Brandse, R.A.Mathôt, D.van der Kleij, T.Rispens, Y.Ashruf, J.M.Jansen, S.Rietdijk, M.Löwenberg, C.Y.Ponsioen, S.Singh, G.R.van den Brink, and G.R.D'Haens, "Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis", *Clin Gastroenterol Hepatol*, **14**(2), 251-8.e1-2(2016).
74. G.R. Lichtenstein, P.Rutgeerts, W.J.Sandborn, B.E.Sands, R.H.Diamond, M.Blank, J.Montello, L.Tang, F.Cornillie, and J.F.Colombel, "A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease", *Am J Gastroenterol*, **107**(7), 1051-63(2012).
75. J.F. Brandse, G.R.van den Brink, M.E.Wildenberg, D.van der Kleij, T.Rispens, J.M.Jansen, R.A.Mathôt, C.Y.Ponsioen, M.Löwenberg, and G.R.D'Haens, "Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis", *Gastroenterology*, **149**(2), 350-5.e2(2015).
76. P. Deepak and E.V., Jr. Loftus, "Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy", *Drug Des Devel Ther*, **10**, 3685-3698(2016).
77. B.G. Feagan, P.Rutgeerts, B.E.Sands, S.Hanauer, J.F.Colombel, W.J.Sandborn, G.Van Assche, J. Axler, H.J.Kim, S.Danese, I.Fox, C.Milch, S.Sankoh, T.Wyant, J.Xu, and A.Parikh, "Vedolizumab as induction and maintenance therapy for ulcerative colitis", *N Engl J Med*, **369**(8), 699-710(2013).
78. S.S. Thomas, N.Borazan, N.Barroso, L.Duan, S.Taroumian, B.Kretzmann, R.Bardales, D.Elashoff, S.Vangala, and D.E.Furst, "Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis", *BioDrugs*, **29**(4), 241-258(2015).
79. C.H. Seow, A.Newman, S.P.Irwin, A.H.Steinhart, M.S.Silverberg, and G.R.Greenberg, "Trough serum

- infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis", *Gut*, 59(1), 49-54(2010).
80. A.S. Strik, G.R.van den Brink, C.Ponsioen, R.Mathot, M.Löwenberg, and G.R.D'Haens, "Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease", *Aliment Pharmacol Ther*, 45(8), 1128-1134(2017).
  81. Y. Xu, O.J.Adedokun, D.Chan, C.Hu, Z.Xu, R.S.Strauss, J.S.Hyams, D.Turner, and H.Zhou, "Population Pharmacokinetics and Exposure-Response Modeling Analyses of Golimumab in Children With Moderately to Severely Active Ulcerative Colitis", *J Clin Pharmacol*, 59(4), 590-604(2019).
  82. A. Sazonovs, N.A.Kennedy, L.Moutsianas, G.A.Heap, D.L.Rice, M.Reppell, *et al.*, "HLA-DQA1\*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease", *Gastroenterology*, 158(1), 189-199(2020).
  83. L.Y. Kwan, S.M.Devlin, J.M.Mirocha, and K.A.Papadakis, "Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease", *Dig Liver Dis*, 40(6), 425-432(2008).
  84. T. Larussa, E.Suraci, M.Lentini, I. Nazionale, L.Gallo, L.Abenavoli, M.Imeneo, F.S.Costanzo, G.Cuda, and F. Luzzi, "High prevalence of polymorphism and low activity of thiopurine methyltransferase in patients with inflammatory bowel disease", *Eur J Intern Med*, 23(3), 273-277(2012).
  85. R.A. Booth, M.T.Ansari, E.Loit, A.C.Trizzo, L.Weeks, S.Doucette, B.Skidmore, M.Sears, R.Sy, and J.Karsh, "Assessment of thiopurine S-methyltransferase activity in patients prescribed thiopurines: a systematic review", *Ann Intern Med*, 154(12), 814-823, w-295-298(2011).
  86. G.J. Walker, J.W.Harrison, G.A.Heap, M.D.Voskuil, V.Andersen, *et al.*, "Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease", *Jama*, 321(8), 773-785(2019).
  87. T. Moriyama, R.Nishii, V.Perez-Andreu, W.Yang, F.A.Klussmann, *et al.*, "NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity", *Nat Genet*, 48(4), 367-373(2016).
  88. E. Schaeffeler, S.U.Jaeger, V.Klumpp, J.J.Yang, S.Igel, L.Hinze, M.Stanulla, and M.Schwab, "Impact of NUDT15 genetics on severe thiopurine-related hematotoxicity in patients with European ancestry", *Genet Med*, 21(9), 2145-2150(2019).
  89. R. Lauro, F.Mannino, N.Irrera, F.Squadrito, D.Altavilla, G.Squadrito, G.Pallio, and A.Bitto, "Pharmacogenetics of Biological Agents Used in Inflammatory Bowel Disease: A Systematic Review", *Biomedicines*, 9(12), (2021).
  90. G. Cui, Q.Fan, Z.Li, R.Goll, and J.Florholmen, "Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease: Current and novel biomarkers", *EBioMedicine*, 66, 103329(2021).
  91. T. Wysocki and A.Paradowska-Gorycka, "Pharmacogenomics of Anti-TNF Treatment Response Marks a New Era of Tailored Rheumatoid Arthritis Therapy", *Int J Mol Sci*, 23(4), 2366 (2022).
  92. J. Sode, S.Bank, U.Vogel, P.S.Andersen, S.B.Sørensen, A.B.Bojesen, *et al.*, "Genetically determined high activities of the TNF-alpha, IL23/IL17, and NFkB pathways were associated with increased risk of ankylosing spondylitis", *BMC Med Genet*, 19(1), 165(2018).
  93. F. Degenhardt, A.Dirmeier, R.Lopez, S.Lang, C.Kunst, D.Roggenbuck, D.Reinhold, S.Szymczak, G.Rogler, F.Klebl, A.Franke, and F.Rieder, "Serologic Anti-GP2 Antibodies Are Associated with Genetic Polymorphisms, Fibrostenosis, and Need for Surgical

- Resection in Crohn's Disease", *Inflamm Bowel Dis*, 22(11), 2648-2657(2016).
94. T. Coelho, G.Andreoletti, J.J.Ashton, A.Batra, N.A.Afzal, Y.Gao, A.P.Williams, R.M.Beattie, and S.Ennis, "Genes implicated in thiopurine-induced toxicity: Comparing TPMT enzyme activity with clinical phenotype and exome data in a paediatric IBD cohort", *Sci Rep*, 6, 34658(2016).
  95. H.L. McLeod, E.Y.Krynetski, M.V.Relling, and W.E.Evans, "Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia", *Leukemia*, 14(4), 567-572(2000).
  96. M.V. Relling, M.Schwab, M.Whirl-Carrillo, G.Suarez-Kurtz, C.H.Pui, *et al.*, "Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update", *Clin Pharmacol Ther*, 105(5), 1095-1105(2019).
  97. P.O. Harmand and J.Solassol, "Thiopurine Drugs in the Treatment of Ulcerative Colitis: Identification of a Novel Deleterious Mutation in TPMT", *Genes (Basel)*, 11(10),(2020).
  98. N. Takatsu, T.Matsui, Y.Murakami, H.Ishihara, T.Hisabe, T.Nagahama, S.Maki, T.Beppu, Y.Takaki, F.Hirai, and K.Yao, Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease", *J Gastroenterol Hepatol*, 24(7), 1258-1264(2009).
  99. R. Banerjee, V.V.Ravikanth, P.Pal, G.Bale, U.S.Avanthi, I.Goren, B.G.Girish, S.Mitnala, and D.N.Reddy, "NUDT15 C415T variant compared with TPMT genotyping in predicting azathioprine-induced leucopenia: prospective analysis of 1014 inflammatory bowel disease patients in India", *Aliment Pharmacol Ther*, 52(11-12), 1683-1694(2020).
  100. H.H. Wang, Y.He, H.X.Wang, C.L.Liao, Y. Peng, L.J.Tao, W.Zhang, and H.X.Yang, "Comparison of TPMT and NUDT15 polymorphisms in Chinese patients with inflammatory bowel disease", *World J Gastroenterol*, 24(8), 941-948(2018).
  101. R.M. Weinshilboum and S.L.Sladek, "Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity", *Am J Hum Genet*, 32(5), 651-662(1980).
  102. M.D. Voskuil, A.Bangma, R.K.Weersma, and E.A.M.Festen, "Predicting (side) effects for patients with inflammatory bowel disease: The promise of pharmacogenetics", *World J Gastroenterol*, 25(21), 2539-2548(2019).
  103. R. Nishii, T.Moriyama, L.J.Janke, W.Yang, C.C.Suiter, T.N.Lin, *et al.*, "Preclinical evaluation of NUDT15-guided thiopurine therapy and its effects on toxicity and antileukemic efficacy", *Blood*, 131(22), 2466-2474(2018).
  104. T. Moriyama, Y.L.Yang, R.Nishii, H.Ariffin, C.Liu, T.N.Lin, W.Yang, D.T.Lin, C.H. Yu, S.Kham, C.H.Pui, W.E.Evans, S.Jeha, M.V.Relling, A.E.Yeoh, and J.J.Yang, "Novel variants in NUDT15 and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry", *Blood*, 130(10), 1209-1212(2017).
  105. R. Choi, M.N.Lee, K.Kim, S.Y.Baek, T.J.Kim, Hong S.N., Kim Y.H., and Lee S.Y., "Effects of various genetic polymorphisms on thiopurine treatment-associated outcomes for Korean patients with Crohn's disease", *Br J Clin Pharmacol*, 86(11), 2302-2313(2020).
  106. J.A. Duley, A.A. Somogyi, and J.H.Martin, "The future of thiopurine pharmacogenomics", *Pharmacogenomics*, 13(14), 1549-1552(2012).
  107. M.N. Lee, B.Kang, S.Y.Choi, M.J.Kim, S.Y.Woo, J.W.Kim, Y.H.Choe, and S.Y.Lee, "Relationship between azathioprine dosage, 6-thioguanine nucleotide levels, and therapeutic response in pediatric patients with IBD treated with azathioprine", *Inflamm Bowel Dis*, 21(5), 1054-1062(2015).
  108. A. Citterio-Quentin, M.Moulsma, Gustin M.P., and Boulieu R., *ITPA Activity in Adults and Children Treated With or Without Azathioprine: Relationship*

- Between TPMT Activity, Thiopurine Metabolites, and Co-medications*", ***Ther Drug Monit***, 39(5), 483-491(2017).
109. J.Y. Chang, S.J. Park, E.S.Jung, S.A.Jung, C.M.Moon, J.Chun, J.J.Park, E.S.Kim, Y.Park, T.I.Kim, W.H.Kim, and J.H.Cheon, "Genotype-based Treatment With Thiopurine Reduces Incidence of Myelosuppression in Patients With Inflammatory Bowel Diseases", ***Clin Gastroenterol Hepatol***, 18(9), 2010-2018.e2(2020).
  110. S. Chen, W.Z.Tan, N.Sutiman, C.Lim, S.S.Lee, W.F.Leong, M.Tjai, C.Wang, C.S.C.Kong, S.W.Chuah, B.J.Schwender, W.Chan, H.H.Shim, W.C.Lim, Khor C.C., K.L.Ling, and B.Chowbay, "An intronic *FTO* variant rs16952570 confers protection against thiopurine-induced myelotoxicities in multiethnic Asian IBD patients", ***Pharmacogenomics J***, 20(3), 505-515(2020).
  111. A. Wilson, L.E.Jansen, R.V.Rose, J.C.Gregor, T.Ponich, N.Chande, R.Khanna, B.Yan, V.Jairath, N.Khanna, M.Sey, M.Beaton, K.McIntosh, W.A.Teft, and R.B.Kim, "HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of azathioprine-induced pancreatitis in patients with inflammatory bowel disease", ***Aliment Pharmacol Ther***, 47(5), 615-620(2018).
  112. A. Wilson, C. Peel, Q.Wang, A.D.Pananos, and R.B.Kim, "HLADQA1\*05 genotype predicts anti-drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease", ***Aliment Pharmacol Ther***, 51(3), 356-363(2020).
  113. S. Bek, J.V.Nielsen, A.B.Bojesen, A.Franke, S.Bank, U.Vogel, and V.Andersen, "Systematic review: genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel diseases", ***Aliment Pharmacol Ther***, 44(6), 554-67(2016).
  114. P. Romero-Cara, D.Torres-Moreno, J. Pedregosa, J.A.Vílchez, M.S.García-Simón, G.Ruiz-Merino, S.Morán-Sanchez, and P.Conesa-Zamora, "A FCGR3A Polymorphism Predicts Anti-drug Antibodies in Chronic Inflammatory Bowel Disease Patients Treated With Anti-TNF", ***Int J Med Sci***, 15(1), 10-15(2018).
  115. D. Lacruz-Guzmán, D.Torres-Moreno, F.Pedrero, P. Romero-Cara, I. García-Tercero, J. Trujillo-Santos, and P.Conesa-Zamora, "Influence of polymorphisms and TNF and IL1 $\beta$  serum concentration on the infliximab response in Crohn's disease and ulcerative colitis", ***Eur J Clin Pharmacol***, 69(3), 431-438(2013).
  116. E.S. Jung, K.W.Choi, S.W.Kim, M. Hübenthal, S.Mucha, J.Park, Z.Park, D.Ellinghaus, S. Schreiber, A. Franke, W.Y.Oh, and J.H.Cheon, "ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases", ***J Gastroenterol Hepatol***, 34(10), 1727-1735(2019).
  117. A. Di Paolo, E. Arrigoni, G.Luci, F. Cucchiara, R.Danesi, and S.Galimberti, "Precision Medicine in Lymphoma by Innovative Instrumental Platforms", ***Front Oncol***, 9, 1417(2019).
  118. M.C. Dubinsky, L.Mei, M.Friedman, T.Dhere, T.Haritunians, H. Hakonarson, C.Kim, J.Glessner, S.R.Targan, D.P.McGovern, K.D.Taylor, and J.I.Rotter, "Genome wide association (GWA) predictors of anti-TNF $\alpha$  therapeutic responsiveness in pediatric inflammatory bowel disease", ***Inflamm Bowel Dis***, 16(8),1357-66(2010).
  119. K.E. Burke, H.Khalili, J.J.Garber, T.Haritunians, D.P.B.McGovern, R.J.Xavier, and A.N.Ananthakrishnan, "Genetic Markers Predict Primary Nonresponse and Durable Response to Anti-Tumor Necrosis Factor Therapy in Ulcerative Colitis", ***Inflamm Bowel Dis***, 24(8), 1840-1848(2018).
  120. S.E. Telesco, C.Brodmerkel, H. Zhang, L.L.Kim, J. Johanns, A.Mazumder, K.Li, *et al.*, "Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis", ***Gastroenterology***, 155(4), 1008-1011.e8(2018).
  121. N.C. Kaneider and A. Kaser, "Personalized Treatment in Inflammatory

- Bowel Disease: For Another Time", *Gastroenterology*, 155(4), 963-964(2018).
122. M.H. Wang, J.J.Fritton, L.E.Raffals, J.A.Leighton, S.F.Pasha, M.F.Picco, K.C.Cushing, K.Monroe, B.D.Nix, R.D.Newberry, and W.A.Faubion, "Novel Genetic Risk Variants Can Predict Anti-TNF Agent Response in Patients With Inflammatory Bowel Disease", *J Crohns Colitis*, 13(8), 1036-1043(2019).
  123. S. Salvador-Martín, I.Raposo-Gutiérrez, V.M.Navas-López, C.Gallego-Fernández, A.Moreno-Álvarez, *et al.*, "Gene Signatures of Early Response to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease", *Int J Mol Sci*, 21(9),(2020).
  124. R. Prieto-Pérez, B.Almoguera, T.Cabaleiro, H.Hakonarson, and F.Abad-Santos, "Association between Genetic Polymorphisms and Response to Anti-TNFs in Patients with Inflammatory Bowel Disease", *Int J Mol Sci*, 17(2), 225(2016).
  125. C.J. Gargallo-Puyuelo, V.Laredo, and F.Gomollón, "Thiopurines in Inflammatory Bowel Disease. How to Optimize Thiopurines in the Biologic Era?", *Front Med (Lausanne)*, 8, 681907(2021).
  126. S.O. Adegbola, K.Sahnan, J.Warusavitarne, A.Hart, and P.Tozer, "Anti-TNF Therapy in Crohn's Disease", *Int J Mol Sci*, 19(8),(2018).
  127. M. Ovacik and K.Lin, "Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development", *Clin Transl Sci*, 11(6), 540-552(2018).
  128. M. van der Have, B.Oldenburg, A.A.Kaptein, J.M.Jansen, R.C.Scheffer, B.A.van Tuyl, A.E.van der Meulen-de Jong, M.Pierik, P.D.Siersema, M.G.van Oijen, and H.H.Fidder, "Non-adherence to Anti-TNF Therapy is Associated with Illness Perceptions and Clinical Outcomes in Outpatients with Inflammatory Bowel Disease: Results from a Prospective Multicentre Study", *J Crohns Colitis*, 10(5), 549-555(2016).
  129. H.H. Fidder, M.M.Singendonk, M.van der Have, B.Oldenburg, and M.G.van Oijen, "Low rates of adherence for tumor necrosis factor- $\alpha$  inhibitors in Crohn's disease and rheumatoid arthritis: results of a systematic review", *World J Gastroenterol*, 19(27), 4344-4350(2013).
  130. J.P. Gisbert, A.C.Marín, A.G.McNicholl, and M.Chaparro, "Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed", *Aliment Pharmacol Ther*, 41(7), 613-623(2015).
  131. G.R. Venkataraman and M.A.Rivas, "Rare and common variant discovery in complex disease: the IBD case study", *Hum Mol Genet*, 28(R2), R162-R169(2019).
  132. E. Uffelmann, Q.Q.Huang, N.S.Munung, J.de Vries, Y.Okada, Martin A.R., H.C.Martin, T.Lappalainen, and D.Posthuma, "Genome-wide association studies", *Nat Rev Methods Primers*, 1(1), 59(2021).
  133. P.L. Kozuch and S.B.Hanauer, "Treatment of inflammatory bowel disease: a review of medical therapy", *World J Gastroenterol*, 14(3), 354-377(2008).
  134. X. Roblin, N.Williet, G.Boschetti, J.M.Phelip, E.Del Tedesco, A.E.Berger, P.Vedrine, G.Duru, L.Peyrin-Biroulet, S. Nancey, B.Flourie, and S.Paul, "Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial", *Gut*, 69(7), 1206-1212(2020).
  135. A. Bangma, M.D.Voskuil, W.T.C.Uniken Venema, H.Brugge, S.Hu, P.Lanting, L.Franke, G.Dijkstra, E.A.M.Festen, and R.K.Weersma, "Predicted efficacy of a pharmacogenetic passport for inflammatory bowel disease", *Aliment Pharmacol Ther*, 51(11), 1105-1115(2020).
  136. M. Rosario, J.L.French, N.L. Dirks, S.Sankoh, A.Parikh, *et al.*, "Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease", *J Crohns Colitis*, 11(8), 921-929(2017).
  137. R.L. Sluiter, C.Van Marrewijk, D.De Jong, H.Scheffer, H.J.Guchelaar, *et al.*, "Genotype-Guided Thiopurine Dosing

- Does not Lead to Additional Costs in Patients With Inflammatory Bowel Disease", *J Crohns Colitis*, 13(7), 838-845(2019).
138. A. Zimdahl Kahlin, S.Helander, K.Skoglund, P.Söderkvist, L.G.Mårtensson, and M.L.Appell, "Comprehensive study of thiopurine methyltransferase genotype, phenotype, and genotype-phenotype discrepancies in Sweden", *Biochem Pharmacol*, 164, 263-272(2019).
  139. M. Grundmann and I.Kacírová, "[Significance of TDM, phenotyping and genotyping for the correct drug dosage]", *Cas Lek Cesk*, 149(10), 482-487(2010).
  140. M. Li, Y.Han, T.T.Wu, Y.Feng, and H.B.Wang, "Tumor necrosis factor alpha rs1800629 polymorphism and risk of cervical lesions: a meta-analysis", *PLoS One*, 8(8), e69201(2013).
  141. R. Lauro, F.Mannino, N.Irrera, F.Squadrito, D.Altavilla, G.Squadrito, G.Pallio, and A. Bitto, "Pharmacogenetics of Biological Agents Used in Inflammatory Bowel Disease: A Systematic Review", *Biomedicines*, 9, 1748(2021).
  142. L. E. Magosi, A.Goel, J.C.Hopewell, and M. Farrall, "Identifying systematic heterogeneity patterns in genetic association meta-analysis studies", *PLoS Genet*, 13(5), e1006755(2017).
  143. K. Lindpaintner, "Pharmacogenetics and the future of medical practice", *Br J Clin Pharmacol*, 54(2), 221-230(2002).
  144. B.J. van den Bosch and M.J.Coenen, "Pharmacogenetics of inflammatory bowel disease", *Pharmacogenomics*, 22(1), 55-66(2021).
  145. J.J. Yang, M.Whirl-Carrillo, S.A.Scott, A.J.Turner, M.Schwab, Y.Tanaka, G.Suarez-Kurtz, E.Schaeffeler, T.E.Klein, N.A.Miller, and A.Gaedigk, "Pharmacogene Variation Consortium Gene Introduction: NUDT15", *Clin Pharmacol Ther*, 105(5): p. 1091-1094 (2019).



## نشرة العلوم الصيدلانية جامعة أسيوط



### دور تعدد الأشكال الجيني في الأزوثيوبيرين والعلاج البيولوجي. الاستجابة السريرية والسمية لدى مرضى التهاب الأمعاء

نشوى الطنطاوي<sup>١</sup> - أميرة بقاسم<sup>٢</sup> - إسلام عبد الحميد الزيايدي<sup>٣</sup> - أحمد أ البري<sup>٤</sup> - ليلي محمد صلاح<sup>٥</sup> - محمد عبد الرحيم<sup>٦\*</sup>

<sup>١</sup> قسم الصيدلة الإكلينيكية ، كلية الصيدلة ، جامعة حورس ، دمياط الجديدة ، مصر

<sup>٢</sup> قسم الصيدلة الإكلينيكية وممارسة الصيدلة ، كلية الصيدلة ، جامعة دمنهور ، مصر

<sup>٣</sup> قسم أمراض الكبد والجهاز الهضمي ، كلية الطب ، جامعة المنصورة ، مصر

<sup>٤</sup> قسم الصيدلة ، كلية الطب ، جامعة بني سويف ، مصر

<sup>٥</sup> قسم الباثولوجيا الإكلينيكية ، كلية الطب ، جامعة المنصورة ، مصر

<sup>٦</sup> قسم الصيدلة الإكلينيكية ، كلية الصيدلة ، جامعة بني سويف ، مصر

يتضمن مرض التهاب الأمعاء مجموعة متنوعة من الحالات ، لا سيما مرض كرون و التهاب القولون التقرحي. يتميز مرض التهاب الأمعاء بعملية التهابية مزمنة في أمعاء المريض. تهدف هذه المراجعة إلى تلخيص علم الوراثة الدوائية للبيولوجيا المعتمدة لـ مرض التهاب الأمعاء والعلاقة مع إنزيمات استقلاب الأزوثيوبيرين والتفاعلات الضائرة ، وبالتالي إبراز العلاقة المحتملة بين تعدد الأشكال المعين والاستجابة العلاجية. لذلك ، قمنا بمراجعة ومناقشة أنشطة بروتوكولات التهاب القولون التقرحي التي تستخدم الأجسام المضادة وحيدة النسيلة مع إيلاء اهتمام خاص لتكامل الإجراءات الأخرى التي تهدف إلى استغلال الأدوية الأكثر فاعلية وأماناً لحالات مرض التهاب الأمعاء.

شهد العلاج الدوائي لـ مرض التهاب الأمعاء (مرض كرون و التهاب القولون التقرحي) تقدماً كبيراً مع ظهور التهاب القولون التقرحي التي لها خصائص حركية دوائية غريبة تميزها عن العوامل الكيميائية ، مثل امينوسيكليين ، ومضادات الأيض (مثل الأزوثيوبيرين ، ٦-مركابتوبورين) ، و الميثوتريكسات) والعوامل المثبطة للمناعة (المنشطات والسيكلوسبورين). ولكن ، أظهرت الدراسات السريرية أن المواد البيولوجية قد يكون لها تنوع حركي دوائي يمكن أن يؤثر على النتائج السريرية المتوقعة ، بما يتجاوز ظواهر المقاومة الأولية.

وبالتالي ، يتم تطبيق بروتوكولات مراقبة الأدوية العلاجية على جرعات الأدوية وفقاً لمستويات التهاب القولون التقرحي في المصل المطلوبة. يهدف هذا إلى تعظيم التأثيرات الإيجابية لـ التهاب القولون التقرحي وتقليل السمية.

ولكن ، قد يؤدي وجود تعدد أشكال وراثي معين في المرضى إلى تحديد نتيجة مختلفة استجابة للعلاج ، مما يشير إلى عدم تجانس الفعالية بين حالات مرض التهاب الأمعاء. في الواقع ، أظهرت العديد من التقارير ارتباطات مهمة بين تعدد الأشكال والاستجابة للبيولوجيا. في الختام ، يمكن أن يكون تحسين علم الوراثة الدوائية TNF- $\alpha$  و TNFR و IL-1 هو أفضل نهج نحو العلاج المستهدف لمرض التهاب الأمعاء. أنسب العوامل البيولوجية لكل حالة. أيضًا ، قد تؤدي إضافة الواسمات الدوائية (بما في ذلك التركيزات المصلية أو الخلوية أو الأنسجة لـ TNF- $\alpha$  و IL-8 إلى تعزيز الأداء التنبئي للنماذج ، وفي النهاية ، السيطرة على المرض مع تحسن كبير في نوعية الحياة.